The Chimeric E2A-HLF Transcription Factor Abrogates p53-Induced Apoptosis in Myeloid Leukemia Cells

Leukemic lymphoblasts expressing the E2A-HLF oncoprotein possess wild-type p53 genes, but do not undergo apoptosis in response to DNA damage. Experimentally, E2A-HLF prevents apoptosis due to growth factor deprivation or γ-irradiation in interleukin-3 (IL-3)–dependent murine pro-B cells. To directly test the chimeric protein’s ability to abrogate p53-mediated cell death, we used mouse myeloid leukemia cells (M1p53tsval) that constitutively express a temperature-sensitive (ts) mutant p53 gene and undergo apoptosis when p53 assumes an active wild-type configuration. This effect is blocked by treatment with IL-6, which allows the cells to survive in culture despite wild-type p53 activation. We introduced E2A-HLF into M1p53tsval cells and found that they were resistant to p53-mediated apoptosis and that E2A-HLF effectively substituted for the survival functions of IL-6. The expression of p53-responsive genes such as p21 and Bax was upregulated normally, suggesting that E2A-HLF acts downstream of p53 to block execution of the p53-induced apoptotic program. NFIL3, a growth factor-regulated bZIP protein that binds to the same DNA-consensus site as E2A-HLF, delays apoptosis in IL-3–dependent pro-B cells deprived of growth factor. By contrast, in the present study, enforced expression of NFIL3 failed to protect M1p53tsval cells from p53-dependent apoptosis and actively antagonized the ability of IL-6 to rescue cells from that fate, consistent with its role as either a transcriptional repressor or activator, depending on the cell type in which it is expressed. We conclude that the E2A-HLF chimera abrogates p53-induced apoptosis in leukemic cells, possibly through the transcriptional modulation of cell death pathways that are activated by p53 in response to DNA damage. © 1998 by The American Society of Hematology.

[1]  A T Look,et al.  Oncogenic transcription factors in the human acute leukemias. , 1997, Science.

[2]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[3]  J L Cleveland,et al.  Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[5]  M. Kastan,et al.  Role of p53 in apoptosis. , 1997, Advances in pharmacology.

[6]  H. Horvitz,et al.  Transcriptional regulator of programmed cell death encoded by Caenorhabditis elegans gene ces-2 , 1996, Nature.

[7]  A. Look,et al.  Reversal of apoptosis by the leukaemia-associated E2A–HLF chimaeric transcription factor , 1996, Nature.

[8]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[9]  John Calvin Reed,et al.  Proapoptotic Protein Bax Heterodimerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct from BH1 and BH2 (*) , 1996, The Journal of Biological Chemistry.

[10]  T. Jacks,et al.  Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells. , 1996, Oncogene.

[11]  S. Hunger,et al.  Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. , 1996, Blood.

[12]  Wei Zhang,et al.  Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter , 1995, Molecular and cellular biology.

[13]  M. Roussel,et al.  Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.

[14]  Stephen,et al.  Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. , 1995, Blood.

[15]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[16]  P. Workman.  To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo? , 1995, Human & experimental toxicology.

[17]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[18]  C. Pui.  Medical progress : childhood leukemias , 1995 .

[19]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[20]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[21]  T. Inaba,et al.  DNA-binding specificity and trans-activating potential of the leukemia-associated E2A-hepatic leukemia factor fusion protein , 1994, Molecular and cellular biology.

[22]  Ian G. Cowell,et al.  Transcriptional repression by the human bZIP factor E4BP4: definition of a minimal repression domain , 1994, Nucleic Acids Res..

[23]  R. Ellis,et al.  Control of germ cell differentiation in Caenorhabditis elegans. , 1994, Ciba Foundation symposium.

[24]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[25]  A. Kimchi,et al.  p53-mediated cell death: relationship to cell cycle control , 1993, Molecular and cellular biology.

[26]  M. Cleary,et al.  Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. , 1992, Genes & development.

[27]  S. Raimondi,et al.  Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. , 1992, Science.

[28]  H. Hurst,et al.  Transcriptional repression by a novel member of the bZIP family of transcription factors , 1992, Molecular and cellular biology.

[29]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[30]  O. Witte,et al.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias , 1991, Molecular and cellular biology.

[31]  C. R. Mehta,et al.  StatXact : a statistical package for exact non-parametric inference, Cytel Software Corporation, Cambridge, MA, USA , 1990 .